← back to search

Torsten Schaller

Immunomedics (Germany) · DE
Area of research
Virology · Epidemiology
Research interest
Research interests include HIV Research and Treatment, interferon and immune responses, Herpesvirus Infections and Treatments, and Cytomegalovirus and herpesvirus research.
h-index
27
citations
4,245
works
54
NIH funding
primary concept
email

Recent publications

Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy
EMBO Molecular Medicine 2020cited by 59position: middledoi
Development and Validation of an LC–MS-Based Quantification Assay for New Therapeutic Antibodies: Application to a Novel Therapy against Herpes Simplex Virus
ACS Omega 2020cited by 15position: middledoi
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies
Nature Medicine 2017cited by 141position: lastdoi
SAMHD1 protects cancer cells from various nucleoside-based antimetabolites
Cell Cycle 2017cited by 87position: lastdoi
Complex Interplay between HIV-1 Capsid and MX2-Independent Alpha Interferon-Induced Antiviral Factors
Journal of Virology 2016cited by 46position: lastdoi
<scp>TRIM</scp> 5α requires Ube2W to anchor Lys63‐linked ubiquitin chains and restrict reverse transcription
The EMBO Journal 2015cited by 101position: middledoi
Promiscuous RNA Binding Ensures Effective Encapsidation of APOBEC3 Proteins by HIV-1
PLoS Pathogens 2015cited by 92position: middledoi
Nuclear import of SAMHD1 is mediated by a classical karyopherin α/β1 dependent pathway and confers sensitivity to VpxMAC induced ubiquitination and proteasomal degradation
Retrovirology 2014cited by 46position: firstdoi
Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection
Nature 2013cited by 566position: middledoi
HIV-1 capsid undergoes coupled binding and isomerization by the nuclear pore protein NUP358
Retrovirology 2013cited by 119position: middledoi
Evidence for IFNα-induced, SAMHD1-independent inhibitors of early HIV-1 infection
Retrovirology 2013cited by 57position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Michael H. Malim · King's College London5 papers (2013–2016)Caroline Goujon · Centre National de la Recherche Scientifique4 papers (2013–2016)Luis Apolonia · King's College London3 papers (2014–2016)Juliane Kutzner · University Hospital Heidelberg2 papers (2016–2017)Greg J. Towers · Institute of Infection and Immunity2 papers (2013–2015)Darja Pollpeter · King's College London2 papers (2014–2016)Reiner Schulz · King's College London2 papers (2013–2015)Nikolas Herold · Karolinska University Hospital2 papers (2016–2017)Rui Pedro Galão · King's College London1 papers (2013–2013)Rémi Longuespée · Institut National des Sciences Appliquées de Strasbourg1 papers (2020–2020)Lorenzo Bulli · University Hospital Heidelberg1 papers (2016–2016)Margaux Fresnais · Heidelberg University1 papers (2020–2020)Cynthia B. J. Paulin · Science for Life Laboratory1 papers (2017–2017)Hélène Bauby · Zalgen (United States)1 papers (2013–2013) · 1 papers (2013–2013)Olivier Moncorgé · Université Claude Bernard Lyon 11 papers (2013–2013) · 1 papers (2013–2013)Amanda J. Price · Johns Hopkins Medicine1 papers (2013–2013)Tomaž Curk · European Molecular Biology Laboratory1 papers (2015–2015)Devin E. Christensen · Spencer Foundation1 papers (2015–2015)